Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set to invest USD 100 million in the Brazilian market to bolster collaborations with local partners and researchers. The company plans to conduct in-country research not only on vaccines but also on advanced therapeutics, including cell therapy and monoclonal antibody drugs.
The announcement was made by Sinovac’s CEO, Yin Weidong, following a meeting with Brazil’s Minister of Development, Industry, Trade, and Services, Geraldo Alckmin, which took place in Beijing. Specifics regarding the investment targets were not disclosed.
As the host unit of the BRICS Vaccine R&D China Center, Sinovac actively collaborates with numerous universities and research institutes both within China and abroad. The company’s current vaccine research and development projects encompass a broad range of vaccines such as rotavirus vaccines, DTP series combined vaccines, multivalent hand-foot-and-mouth disease vaccines, pneumococcal series vaccines, meningococcal series vaccines, and others aimed at combating respiratory and enteric infectious diseases.- Flcube.com
